Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT

NCT06861348 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphocytic, Acute

Interventions

DRUG: Inotuzumab Ozogamicin±Donor Lymphocyte Infusion

Sponsor

First Affiliated Hospital of Zhejiang University